Articles By Janet Pope, MD, MPH, FRCPC

steroids.prednisone.pills_.jpg

How to properly use steroids in early RA

By Janet Pope, MD, MPH, FRCPC

Guidelines differ on the early treatment of RA – ACR suggests not to use glucocorticoids (GC) and EULAR updated recommendations for RA treatment presented at #EULAR2025 continued to suggest early treatment with MTX and glucocorticoids. We do know that it is not easy to get a significant minority of RA patients off of prednisone.

Read Article
uveitis eye iritis

Putting IL17i into ‘focus’ for SpA-associated uveitis

By Janet Pope, MD, MPH, FRCPC

The longest studied drug for uveitis in SpA has been monocolonal TNFi Abs. Reductions of acute anterior uveitis have been found with etanercept but less impressively than adalimumab, infliximab, and in my opinion less than golimumab and certolizumab pegol. Other data have emerged for JAKi and IL17i, with respect to acute anterior uveitis.

Read Article
Choices

SLE Treatment Landscape: Abundance or Overload?

By Janet Pope, MD, MPH, FRCPC

Imagine a world where the multiple drugs in Phase 2 and 3 trials actually get approved, and we get access to them? I know you may be thinking that I am overly optimistic, but there are so many drugs in development in lupus that we may have true difficulty choosing what to use.

Read Article
Checklist survey

Contemporary lupus nephritis treatment

By Janet Pope, MD, MPH, FRCPC

Outcomes in lupus nephritis are akin to the glass half full. Serial monotherapy is out, as the percentage who achieved a complete renal response was very low and some went to end stage kidney disease (ESKD). Solutions?

Read Article
Pope

Lessons Learned from a Lupus Registry: Two sides of one coin?

By Janet Pope, MD, MPH, FRCPC

I want to talk about a large Canadian registry that sometimes doesn't get as much airtime. Our group is called CaNIOS: Canadian Network for Improved Outcomes in SLE. We've enrolled more than a thousand patients, seen at least annually and some for many years. These patients are incident or prevalent and they've consented to be in the database. So what have we learned looking at kid-onset versus adult-onset lupus?

Read Article
question marks

Emulation trials in SLE: Real or Fake?

By Janet Pope, MD, MPH, FRCPC

Recently a landmark paper was published in A&R studying the results of an emulation trial on SGLT2i (sodium-glucose co-transporter 2 inhibitors) showing benefit in SLE patients with diabetes mellitus (DM), for both renal protection and reducing cardiovascular events, using data from an American large insurance claim database. My colleagues and I were able to write an editorial on this paper and describe emulation trials.

Read Article
question-mark-1872634_640.jpg

ICYMI: JAKi in inflammatory myositis?

By Janet Pope, MD, MPH, FRCPC

Abstract 1731 is a small RCT of baricitinib in inflammatory myositis comparing early start baricitinib to later start.

Read Article
question mark

ICYMI: Are Emulation Trials a Fantasy?

By Janet Pope, MD, MPH, FRCPC

Are emulation ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized controlled trials (RCTs)?

Read Article
light-bulbs-1125016_640.jpg

Off-Label Use of JAK Inhibitors in Orphan Diseases and Other Conditions?

By Janet Pope, MD, MPH, FRCPC

When should you consider off-label use of JAKi?

Read Article
question-mark-1872634_640.jpg

JAKi in inflammatory myositis?

By Janet Pope, MD, MPH, FRCPC

Abstract 1731 is a small RCT of baricitinib in inflammatory myositis comparing early start baricitinib to later start.

Read Article
Profile picture for user Janet Pope, MD, MPH, FRCPC
  • Janet Pope, MD, MPH, FRCPC

  • Dr. Janet Pope is a Professor of Medicine in the Division of Rheumatology at the University of Western Ontario (UWO), Schulich School of Medicine, London, Ontario, Canada.  She is the Division Head in Rheumatology at St. Joseph's Health Centre, London. Her research includes studies in scleroderma, SLE and RA, including outcome measurements, clinical trials and disease manifestations. She has published over 450 peer-reviewed articles, 15 chapters, 500 abstracts and several Cochrane meta-analysis reviews. Mentoring of research students and trainees numbers more than 125. She has received the Distinguished Investigator Award from the Canadian Rheumatology Association, Rheumatologist of the Year from the Ontario Rheumatology Association, Department of Medicine Research Achievement Award, and the Dean’s Award of Excellence in Research. She has been inducted into the Canadian Academy of Health Sciences.

     

×